Yujiro Higuchi

Yujiro Higuchi

Auto-generated profile, based on publicly available information

Yujiro Higuchi

Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
MAMasahiro Ando
Masahiro Ando
YHYujiro Higuchi
Yujiro Higuchi
JYJun-Hui Yuan
Jun-Hui Yuan
AYAkiko Yoshimura
Akiko Yoshimura
FKFumikazu Kojima
Fumikazu Kojima
HTHiroshi Takashima
Hiroshi Takashima
Background and Objectives: The GAA repeat expansion within the fibroblast growth factor 14 (FGF14) gene has been found to be associated with late‐onset cerebellar ataxia. This study aimed to investigate the genetic causes of cerebellar ataxia in patients in Japan.Methods: We collected a case series of 940 index patients who presented with chronic cerebellar ataxia and remained genetically undiagnosed after our preliminary genetic screening. To investigate the FGF14 repeat locus, we employed an integrated diagnostic strategy that involved fluorescence amplicon length analysis polymerase chain reaction (PCR), repeat‐primed PCR, and long‐read sequencing.Results: Pathogenic FGF14 GAA repeat expansions were detected in 12 patients from 11 unrelated families. The median size of the pathogenic GAA repeat was 309 repeats (range: 270–316 repeats). In these patients, the mean age of onset was 66.9 ± 9.6 years, with episodic symptoms observed in 56% of patients and parkinsonism in 30% of patients. We also detected FGF14 repeat expansions in a patient with a phenotype of multiple system atrophy, including cerebellar ataxia, parkinsonism, autonomic ataxia, and bilateral vocal cord paralysis. Brain magnetic resonance imaging (MRI) showed normal to mild cerebellar atrophy, and a follow‐up study conducted after a mean period of 6 years did not reveal any significant progression.Discussion: This study highlights the importance of FGF14 GAA repeat analysis in patients with late‐onset cerebellar ataxia, particularly when they exhibit episodic symptoms, or their brain MRI shows no apparent cerebellar atrophy. Our findings contribute to a better understanding of the clinical variability of GAA‐FGF14‐related diseases.

1 December 2014 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
AHAkihiro Hashiguchi
Akihiro Hashiguchi
YHYujiro Higuchi
Yujiro Higuchi
MNMiwa Nomura
Miwa Nomura
TNTomonori Nakamura
Tomonori Nakamura
HAHitoshi Arata
Hitoshi Arata
HTHiroshi Takashima
Hiroshi Takashima

11 July 2018 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JYJun-Hui Yuan
Jun-Hui Yuan
YSYusuke Sakiyama
Yusuke Sakiyama
AHAkihiro Hashiguchi
Akihiro Hashiguchi
MAMasahiro Ando
Masahiro Ando
YOYuji Okamoto
Yuji Okamoto
HTHiroshi Takashima
Hiroshi Takashima

29 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMasahiro Ando
Masahiro Ando
YHYujiro Higuchi
Yujiro Higuchi
JYJun-Hui Yuan
Jun-Hui Yuan
AYAkiko Yoshimura
Akiko Yoshimura
TTTakaki Taniguchi
Takaki Taniguchi
HTHiroshi Takashima
Hiroshi Takashima
Various genomic variants were linked to inherited peripheral neuropathies (IPNs), including large duplication/deletion and repeat expansion, making genetic diagnosis challenging. This large case series aimed to identify the genetic characteristics of Japanese patients with IPNs. We collected data on 2695 IPN cases throughout Japan, in which PMP22 copy number variation (CNV) was pre-excluded. Genetic analyses were performed using DNA microarrays, next-generation sequencing-based gene panel sequencing, whole-exome sequencing, CNV analysis, and RFC1 repeat expansion analysis. The overall diagnostic rate and the genetic spectrum of patients were summarized. We identified 909 cases with suspected IPNs, pathogenic or likely pathogenic variants. The most common causative genes were MFN2, GJB1, MPZ, and MME. MFN2 was the most common cause for early-onset patients, whereas GJB1 and MPZ were the leading causes of middle-onset and late-onset patients, respectively. Meanwhile, GJB1 and MFN2 were leading causes for demyelinating and axonal subtypes, respectively. Additionally, we identified CNVs in MPZ and GJB1 genes and RFC1 repeat expansions. Comprehensive genetic analyses explicitly demonstrated the genetic basis of our IPN case series. A further understanding of the clinical characteristics of IPN and genetic spectrum would assist in developing efficient genetic testing strategies and facilitate early diagnosis.

23 August 2024 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
THTakahiro Hobara
Takahiro Hobara
YHYujiro Higuchi
Yujiro Higuchi
MYMari Yoshida
Mari Yoshida
MSMasahito Suehara
Masahito Suehara
MAMasahiro Ando
Masahiro Ando
HTHiroshi Takashima
Hiroshi Takashima
Primary familial brain calcification (PFBC) is a genetic neurological disorder characterized by symmetric brain calcifications that manifest with variable neurological symptoms. This study aimed to explore the genetic basis of PFBC and elucidate the underlying pathophysiological mechanisms. Six patients from four pedigrees with brain calcification were enrolled. Whole-exome sequencing identified two novel homozygous variants, c.488G > T (p.W163L) and c.2135G > A (p.W712*), within the myogenesis regulating glycosidase (MYORG) gene. Cerebellar ataxia (n = 5) and pyramidal signs (n = 4) were predominant symptoms, with significant clinical heterogeneity noted even within the same family. An autopsy of one patient revealed extensive brainstem calcifications, sparing the cerebral cortex, and marked by calcifications predominantly in capillaries and arterioles. The pathological study suggested morphological alterations characterized by shortened foot processes within astrocytes in regions with pronounced calcification and decreased immunoreactivity of AQP4. The morphology of astrocytes in regions without calcification remains preserved. Neuronal loss and gliosis were observed in the basal ganglia, thalamus, brainstem, cerebellum, and dentate nucleus. Notably, olivary hypertrophy, a previously undescribed feature in MYORG-PFBC, was discovered. Neuroimaging showed reduced blood flow in the cerebellum, highlighting the extent of cerebellar involvement. Among perivascular cells constituting the blood-brain barrier (BBB) and neurovascular unit, MYORG is most highly expressed in astrocytes. Astrocytes are integral components of the BBB, and their dysfunction can precipitate BBB disruption, potentially leading to brain calcification and subsequent neuronal loss. This study presents two novel homozygous variants in the MYORG gene and highlights the pivotal role of astrocytes in the development of brain calcifications, providing insights into the pathophysiological mechanisms underlying PFBC associated with MYORG variants.

30 September 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
MAMasahiro Ando
Masahiro Ando
YHYujiro Higuchi
Yujiro Higuchi
JYJun-Hui Yuan
Jun-Hui Yuan
AYAkiko Yoshimura
Akiko Yoshimura
CYChikashi Yano
Chikashi Yano
HTHiroshi Takashima
Hiroshi Takashima
Background: Mitofusin 2 ( MFN2 ) is a major causative gene for axonal Charcot – Marie – Tooth disease type 2A (CMT2A), with a wide phenotypic spectrum. Comprehensive large ‐ scale genotype – phenotype association studies are essential for understanding disease pathogenesis and improved clinical management. Methods: We conducted a nationwide retrospective study of 176 Japanese patients with genetically confirmed pathogenic or likely pathogenic MFN2 variants encompassing clinical, electrophysiological, and genetic characterization. Results: MFN2 was the second most frequent causative gene among 1211 genetically diagnosed inherited peripheral neuropathy cases in Japan. A total of 76 MFN2 variants were identified, including nine novel likely pathogenic variants. Disease onset occurred at a mean age of 11.1 years, with distal motor weakness and tibialis anterior involvement as prominent features. Sensory symptoms were present in ~60% of patients and were more common in cases with longer disease duration. Central and systemic features, including pyramidal signs, optic atrophy, and vocal cord paralysis, were also observed. Electrophysiological studies revealed a predominantly axonal sensorimotor pattern, with relatively preserved upper limb conduction and marked lower limb abnormalities. Importantly, 24 patients (16%) were non‐ambulatory, with earlier onset and greater weakness. Domain‐based analysis further revealed that variant location may influence age at onset. Conclusion: This large‐scale study highlights the genetic and clinical diversity of MFN2 ‐related CMT in Japan. Our findings confirm a motor‐dominant, length‐dependent axonal neuropathy with additional sensory and systemic features in some cases. These results emphasize the importance of early diagnosis, genotype‐informed care, and long‐term follow‐up in managing MFN2 ‐related CMT.